Combined Antimicrobial Blue Light and Antibiotics as a Tool for Eradication of Multidrug-Resistant Isolates of Pseudomonas aeruginosa and Staphylococcus aureus: In Vitro and In Vivo Studies

• Published in: Antioxidants 2022-08, Vol.11 (9), p.1660
• Main Authors: Woźniak, Agata, Grinholc, Mariusz
• Format: Article
• Language: English
• Subjects: Antibiotics; Antimicrobial agents; Bioluminescence; blue light; Cell envelopes; Chloramphenicol; Ciprofloxacin; Colistin; Drug dosages; Drug resistance; Experiments; Fosfomycin; Fusidic acid; Light emitting diodes; Linezolid; Medical research; mouse model; Multidrug resistance; Pathogens; Permeability; Photoinactivation; porphyrins; Pseudomonas aeruginosa; rose bengal; Staphylococcus aureus; Virulence
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox11091660

Increased development of resistance to antibiotics among microorganisms promotes the evaluation of alternative approaches. Within this study, we examined the efficacy of antimicrobial blue light (aBL) with routinely used antibiotics against multidrug-resistant isolates of Pseudomonas aeruginosa and Staphylococcus aureus as combined alternative treatment. In vitro results of this study confirm that both S. aureus and P. aeruginosa can be sensitized to antibiotics, such as chloramphenicol, linezolid, fusidic acid or colistin, fosfomycin and ciprofloxacin, respectively. The assessment of increased ROS production upon aBL exposure and the changes in cell envelopes permeability were also goals that were completed within the current study. Moreover, the in vivo experiment revealed that, indeed, the synergy between aBL and antibiotic (chloramphenicol) occurs, and the results in the reduced bioluminescence signal of the S. aureus Xen31 strain used to infect the animal wounds. To conclude, we are the first to present the possible mechanism explaining the observed synergies among photoinactivation with blue light and antibiotics in the term of Gram-positive and Gram-negative representatives.